Enterprise Value
507.5M
Cash
278.6M
Avg Qtr Burn
-29.67M
Short % of Float
1.41%
Insider Ownership
24.07%
Institutional Own.
41.19%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma | Approved Update | |
Camidanlumab Tesirine (CD25) Details Solid tumor/s, Cancer, Hodgkin Lymphoma | BLA Submission | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Diffuse large B cell lymphoma | Phase 3 Data readout | |
ZYNLONTA + Rituximab Details Blood cancer, Follicular lymphoma | Phase 2 Update | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Blood cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
Mipasetamab Uzoptirine (ADCT-601) (AXL) Details Cancer, Solid tumor/s | Phase 1b Data readout | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1b Data readout | |
ADCT-602 (CD22) Details Acute lymphoblastic leukemia | Phase 1a Data readout | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Diffuse large B cell lymphoma | Failed Discontinued | |
ADCT-901 (targeting KAAG1) Details Solid tumor/s, Cancer | Failed Discontinued |